This is a non-core endpoint: only basic statistics are computed.
See these related core endpoints for full statistics:
Malignant neoplasm of other and unspecified major salivary glands, excluding all cancers (controls excluding all cancers)
C3_SALIVARYNAS_EXALLC
No definition available.
Endpoint definition
↥
Endpoint definition steps |
FinnGen |
|---|---|
Phenotype data |
520210 |
1. Apply sex-specific ruleNone |
520210 |
2. Check conditionsNone |
520210 |
3. Check pre-conditions, main-only, mode, registry filtersRegistry filters:
3 out of 7 registries used, show all original rules. |
265 |
4. Check minimum number of eventsNone |
265 |
5. Include endpointsNone |
265 |
6. Filter based on genotype QC (FinnGen only) |
265 |
Control definitions (FinnGen only)
- Control exclude
- C3_CANCER, C3_CANCER_WIDE_EXALLC
Extra metadata
- First used in FinnGen datafreeze
- DF12
Similar endpoints
↥List of similar endpoints to
Malignant neoplasm of other and unspecified major salivary glands, excluding all cancers (controls excluding all cancers)
based on the number of shared cases.
Similar with more cases:
- Malignant neoplasm of head and neck, excluding all cancers (controls excluding all cancers)
- Malignant neoplasm, excluding all cancers (controls excluding all cancers)
- Malignant neoplasm, wide definition for exclusion
- Malignant neoplasm, wide definition for exclusion, excluding all cancers (controls excluding all cancers)
- Neoplasms
Similar with less cases:
Case counts by codes
↥
Summary Statistics
↥-FinRegistry-
This endpoint is excluded from FinRegistry analyses (omitted endpoint).
-FinnGen-
Key figures
| All | Female | Male | |
|---|---|---|---|
| Number of individuals | 265 | 124 | 141 |
| Unadjusted period prevalence (%) | 0.05 | 0.04 | 0.06 |
| Median age at first event (years) | 61.79 | 57.64 | 65.45 |
-FinnGen-
Age distribution of first events
-FinnGen-
Year distribution of first events
-FinnGen-
Cumulative Incidence Function
Not a core endpoint, no data to show.
CodeWAS (R11)
↥CodeWAS is a tool for exploring the associations between an endpoint and all of the medical codes and drug codes.
This is a new tool, please reach out using the contact form for feedback and improvement ideas.
First, a cohort is built by matching controls to the endpoint cases using year of birth and sex. Then, a Fisher test is done for all the medical codes and drug codes between the cases and controls of this cohort. Codes are reported in the table below if they have −log10(p-value) ≥ 6.
Matched cohort
- Matched cases
- 101
- Matched controls
- 1011
Code
Vocabulary
Description
Odds Ratio
-log10(p)
N matched cases
N matched controls
ELB30
NOMESCO Finland
Excision of submandibular gland
691.1
44.9
41
*
C08.09
ICD-10 Finland
Malignant tumor of the submandibular or submaxillary gland, other or unspecified histology
+∞
34.3
31
*
130
Kela drug reimbursment
Malignant tumour
+∞
33.1
30
*
WF003
NOMESCO Finland
Adjuvant radiotherapy
+∞
33.1
30
*
D11.70
ICD-10 Finland
Gland sublingual
+∞
33.1
30
*
WZC00
NOMESCO Finland
Planning of intervention or health care consultation
10.9
26.5
69
166
PJD81
NOMESCO Finland
Excision of lymph nodes from upper part of neck
+∞
25.0
23
*
EP1AE
NOMESCO Finland
Neck ultrasound examination
32.7
24.5
32
14
PJD71
NOMESCO Finland
Extended sparing excision of cervical lymph nodes
+∞
21.6
20
*
C08.02
ICD-10 Finland
Cystic adenocarcinoma of the submandibular or submaxillary glands
+∞
21.6
20
*
XX3DW
NOMESCO Finland
Time consuming IT work
17.5
20.5
33
27
R22.1
ICD-10 Finland
Localized swelling, mass and lump, neck
19.7
19.7
30
21
8200/3-C08.0
ICD-O-3
Adenoid cystic carcinoma of submandibular gland
+∞
19.4
18
*
H02AB02
ATC
dexamethasone; systemic
201.8
17.0
17
*
C08.00
ICD-10 Finland
Malignant tumor of submandibular or submaxillary gland, not histology
+∞
16.0
15
*
WZC20
NOMESCO Finland
Multidisciplinary treatment meeting
32.9
14.9
19
7
R59.0
ICD-10 Finland
Localized enlarged lymph nodes
62.6
14.3
16
*
EP1CG
NOMESCO Finland
Extensive MRI examination of soft tissue of neck with high intesity magnet
40.3
14.0
17
5
YA1BD
NOMESCO Finland
Extensive CT examination of head and neck for dose design of radiotherapy
+∞
13.9
13
*
WF049
NOMESCO Finland
Radiotherapy of metastasis
+∞
13.9
13
*
ZX012
NOMESCO Finland
Radiotherapy with large shaped fields - isocentric therapy
+∞
13.9
13
*
A04AA02
ATC
granisetron; systemic, transdermal
160.6
13.8
14
*
D11.0
ICD-10 Finland
Benign neoplasm: Parotid gland
23.9
13.0
18
9
WF002
NOMESCO Finland
Radical radiotherapy
+∞
12.8
12
*
ZX090
NOMESCO Finland
Other technic of radiotherapy
+∞
12.8
12
*
WD125
NOMESCO Finland
Demanding cystostatic therapy of methastized malignancy
+∞
12.8
12
*
C79.5
ICD-10 Finland
Secondary malignant neoplasm of bone and bone marrow
+∞
12.8
12
*
Z51.5
ICD-10 Finland
Palliative care
19.1
12.7
19
12
EP1DG
NOMESCO Finland
Very extensive examination of soft tissue of neck with high intesity magnet
73.7
11.9
13
*
PJD41
NOMESCO Finland
Excision of cervical lymph nodes
134.6
11.7
12
*
ZX070
NOMESCO Finland
Intensity modified radiotherapy
+∞
11.7
11
*
D37.00
ICD-10 Finland
Aryepiglottic fold marginal zone
40.1
11.6
14
*
C08.90
ICD-10 Finland
Malignant tumor in unspecified large salivary gland without histology
+∞
10.6
10
*
C83.80
ICD-10 Finland
B-cell lymphoma in marginal zone
+∞
10.6
10
*
N02AA05
ATC
oxycodone; systemic
5.8
10.5
32
74
A07AA02
ATC
nystatin; oral
10.9
10.1
19
21
SAA03
NOMESCO Finland
Extended examination of mouth
4.0
9.9
57
247
A03FA01
ATC
metoclopramide; systemic, rectal
6.6
9.8
26
50
C08.01
ICD-10 Finland
Diverse adenocarcinoma of the mandibular salivary gland
+∞
9.5
9
*
C77.0
ICD-10 Finland
Secondary and unspecified malignant neoplasm: Lymph nodes of head, face and neck
+∞
9.5
9
*
C78.0
ICD-10 Finland
Secondary malignant neoplasm of lung
+∞
9.5
9
*
JN4KR
NOMESCO Finland
Whole body very extensive metabolic PET with CT
+∞
9.5
9
*
C08.0
ICD-10 Finland
Malignant neoplasm: Submandibular gland
+∞
9.5
9
*
WX408
NOMESCO Finland
General anesthesy, balanced
4.4
9.2
38
121
117
Kela drug reimbursment
Leukaemia and other malignant diseases of the blood and bone marrow, and malignant diseases of the lymphatic tissue
26.9
9.1
12
5
XW000
NOMESCO Finland
Bone marrow biopsy
16.3
8.5
13
9
EB1HA
NOMESCO Finland
Panorama tomography of teeth and jaws or similar X-ray examination
3.5
8.4
57
270
9699/3-C08.0
ICD-O-3
Marginal zone B-cell lymphoma, NOS, of submandibular gland
+∞
8.4
8
*
ZX080
NOMESCO Finland
Image guided radiotherapy
+∞
8.4
8
*
YX9AD
NOMESCO Finland
Other CT eamination for dose design of radiotherapy
+∞
8.4
8
*
JN4BD
NOMESCO Finland
Extensive body CT
9.0
8.3
17
22
QAE10
NOMESCO Finland
Excision of other lesion extending through all layers of skin in head or neck
9.8
8.2
16
19
K08.1
ICD-10 Finland
Loss of teeth due to accident, extraction or local periodontal disease
5.6
8.1
24
53
504
Kela drug reimbursment
Conditions requiring daily forced enteral nutrition
48.9
7.8
9
*
YA1AD
NOMESCO Finland
CT examination of head and neck for dose design of radiotherapy
48.9
7.8
9
*
C08.94
ICD-10 Finland
Mucoepidermoid carcinoma of an unspecified large salivary gland
+∞
7.4
7
*
JN5DR
NOMESCO Finland
PET-CT of upper body metabolism
+∞
7.4
7
*
8200/3-C08.9
ICD-O-3
Adenoid cystic carcinoma of major salivary gland, NOS
+∞
7.4
7
*
8430/3-C08.0
ICD-O-3
Mucoepidermoid carcinoma of submandibular gland
+∞
7.4
7
*
WB103
NOMESCO Finland
Simple adjuvant cytostatic therapy
+∞
7.4
7
*
Z51.0
ICD-10 Finland
Radiotherapy session
+∞
7.4
7
*
A04AA55
ATC
palonosetron, combinations; systemic
+∞
7.4
7
*
YA1VG
NOMESCO Finland
MRI examination of head and neck with high intesity magnet for dose design of radiotherapy
+∞
7.4
7
*
L02BB03
ATC
bicalutamide; oral
+∞
7.4
7
*
WZC30
NOMESCO Finland
Teaching
4.7
6.5
22
56
L03AA02
ATC
filgrastim; parenteral
74.3
6.5
7
*
JN6BD
NOMESCO Finland
Extensive CT of torso and neck
74.3
6.5
7
*
JN6AD
NOMESCO Finland
CT of torso and neck
28.6
6.3
8
*
EN1BD
NOMESCO Finland
Very extensive CT examination of mouth and soft tissues of neck
28.6
6.3
8
*
YA1CD
NOMESCO Finland
Very extensive CT examination of head and neck for dose design of radiotherapy
+∞
6.3
6
*
EJB30
NOMESCO Finland
Excision of lesion of floor of mouth
+∞
6.3
6
*
C08.91
ICD-10 Finland
Adenocarcinoma of mixed cell type in unspecified large salivary gland
+∞
6.3
6
*
C79.8
ICD-10 Finland
Secondary malignant neoplasm of other specified sites
+∞
6.3
6
*
C08.9
ICD-10 Finland
Malignant neoplasm: Major salivary gland, unspecified
+∞
6.3
6
*
EHB00
NOMESCO Finland
Excision of lesion of palate
+∞
6.3
6
*
EN1AD
NOMESCO Finland
CT examination of mouth and soft tissues of neck
+∞
6.3
6
*
A04AD12
ATC
aprepitant; systemic
+∞
6.3
6
*
B01AB10
ATC
tinzaparin; parenteral
8.9
6.0
12
15
N02AB03
ATC
fentanyl; nasal, sublingual, transdermal
16.3
6.0
9
6
LabWAS
↥OMOP Concept
People with measurements
Mean N measurements
Mean measured value
(ID) Name
N Cases
N Controls
OR
-log10(p)
cases
controls
cases
controls
unit
-log10(p)
N cases
N controls
65
22
38.82
101.12
1.4
1.1
—
—
—
0
0
139
837
2.39
10.97
4.2
3.4
34.8
35.8
g/l
1.40
128
772
136
816
2.37
10.76
4.0
3.6
—
—
—
0
0
161
1053
2.35
10.25
12.3
6.4
4.2
4.2
e9/l
0.20
150
916
110
627
2.29
9.53
4.2
2.0
2.4
2.3
mmol/l
0.05
97
516
145
981
2.06
7.61
8.9
3.7
10.2
11.8
umol/l
2.17
139
915
139
952
1.97
6.78
6.6
5.4
1.2
1.2
mmol/l
0.23
107
811
20
57
3.71
6.29
2.1
2.5
1.1
1.6
mg/l
3.42
20
51
10
8
12.93
6.13
3.2
1.6
14.6
12.8
ug/l
—
10
8
127
871
1.88
5.92
5.6
4.9
1.2
1.2
mmol/l
1.11
109
765
188
1490
1.90
5.28
10.2
5.3
80.3
75.3
u/l
0.75
174
1360
41
195
2.30
5.16
4.1
3.0
—
—
—
0
0
71
418
1.95
5.15
2.1
2.0
—
—
—
0
0
33
153
2.32
4.40
3.0
2.0
70.1
61.1
ml/min/173m2
0.60
11
58
47
252
2.05
4.39
4.9
4.9
1.0
1.0
mmol/l
0.93
42
221
10
22
4.68
4.34
1.2
1.2
—
—
—
0
0
155
1207
1.68
4.13
5.2
4.0
6.9
6.7
mmol/l
0.50
146
1112
26
113
2.44
4.00
1.3
1.3
—
—
—
0
0
6
6
10.19
3.51
1.2
1.0
—
—
—
0
0
7
10
7.15
3.38
5.6
1.9
2.1
5.0
nmol/l
—
7
10
13
45
2.99
3.07
1.2
1.5
—
—
—
0
0
6
8
7.64
3.07
2.2
2.4
—
—
—
0
0
49
302
1.76
2.99
2.1
1.7
—
—
—
0
0
11
35
3.24
2.96
1.4
1.3
—
—
—
0
0
45
272
1.79
2.93
9.1
7.2
—
—
—
0
0
9
22
4.20
2.91
1.0
1.0
—
—
—
0
0
15
59
2.63
2.84
3.3
2.9
—
—
—
0
0
36
210
1.83
2.63
6.5
6.0
1.6
1.6
mmol/l
0.00
28
163
36
211
1.82
2.59
6.4
5.9
5.5
5.2
kpa
0.88
29
202
36
211
1.82
2.59
6.4
5.9
15.6
11.5
kpa
2.17
29
203
10
34
3.02
2.44
1.1
1.2
—
—
—
0
0
18
350
0.48
2.43
1.2
1.3
57.0
12.7
u/ml
—
7
130
20
368
0.51
2.29
1.2
1.3
131.6
38.4
iu/ml
—
8
114
35
212
1.75
2.27
1.7
1.6
—
—
—
0
0
10
37
2.77
2.13
1.1
1.2
—
—
—
0
0
8
25
3.27
2.11
1.1
1.2
—
—
—
0
0
22
118
1.94
2.09
1.5
1.5
—
—
—
0
0
34
211
1.70
2.04
2.0
1.7
—
—
—
0
0
172
1504
1.41
1.90
4.2
4.3
12.8
11.7
mm/h
0.57
154
1363
13
59
2.27
1.87
2.0
1.4
20.9
28.7
mg/l
1.48
13
49
13
59
2.27
1.87
2.0
1.4
26.6
41.7
mg/l
1.64
13
49
7
23
3.10
1.81
1.1
1.2
—
—
—
0
0
8
29
2.81
1.80
1.1
1.2
—
—
—
0
0
219
2017
1.49
1.69
21.5
12.4
29.9
22.9
mg/l
1.97
185
1545
7
25
2.85
1.66
1.1
1.2
—
—
—
0
0
229
2133
1.54
1.63
22.8
15.1
139.2
139.9
mmol/l
2.90
220
2060
7
158
0.43
1.61
1.7
1.8
—
—
—
0
0
11
51
2.21
1.52
1.9
1.4
—
—
—
0
0
14
72
2.00
1.52
1.7
1.6
—
—
—
0
0
229
2142
1.51
1.49
22.7
15.2
4.0
4.0
mmol/l
0.40
221
2070
9
38
2.42
1.47
1.3
1.2
—
—
—
0
0
9
38
2.42
1.47
1.3
1.2
—
—
—
0
0
42
565
0.70
1.35
1.4
1.7
1.5
1.3
mmol/l
0.75
31
470
86
704
1.33
1.32
3.3
3.0
—
—
—
0
0
6
24
2.53
1.31
1.2
1.1
—
—
—
0
0
5
18
2.81
1.29
1.0
1.1
—
—
—
0
0
5
18
2.81
1.29
1.0
1.1
—
—
—
0
0
5
18
2.81
1.29
1.0
1.1
—
—
—
0
0
9
45
2.03
1.24
1.6
1.4
—
—
—
0
0
5
19
2.66
1.22
1.2
1.1
—
—
—
0
0
8
38
2.14
1.19
1.3
1.2
—
—
—
0
0
5
20
2.53
1.15
1.2
1.1
—
—
—
0
0
5
20
2.53
1.15
1.2
1.1
—
—
—
0
0
5
20
2.53
1.15
1.2
1.1
—
—
—
0
0
5
20
2.53
1.15
1.2
1.1
—
—
—
0
0
5
20
2.53
1.15
1.2
1.1
—
—
—
0
0
64
785
0.76
1.14
4.6
3.9
2.0
2.0
ug/l
0.12
52
680
76
628
1.29
1.08
2.3
2.1
49.1
58.1
u/l
2.02
70
579
94
801
1.27
1.05
2.4
2.3
80.7
77.7
nmol/l
0.52
86
702
5
22
2.30
1.04
1.2
1.2
—
—
—
0
0
30
407
0.70
1.02
1.2
1.2
0.5
1.8
u/ml
—
10
104
82
692
1.27
0.98
2.7
3.1
1007.1
1262.2
ng/l
0.52
72
576
165
1511
1.24
0.94
4.0
3.8
14.9
14.9
pmol/l
0.02
140
1350
11
63
1.78
0.91
1.6
1.4
—
—
—
0
0
7
127
0.54
0.91
1.3
1.6
—
—
—
0
0
17
111
1.57
0.90
2.1
1.6
—
—
—
0
0
63
523
1.27
0.86
5.4
3.9
0.0
0.0
estimate
0.00
25
162
41
321
1.33
0.86
23.9
23.7
1.5
1.4
inr
—
7
52
226
2160
1.31
0.82
24.3
14.8
78.6
79.8
umol/l
0.33
226
2160
64
541
1.24
0.75
3.3
3.0
0.3
0.4
e6/l
0.61
54
390
52
621
0.80
0.73
3.5
3.6
18.9
24.2
%
2.07
29
283
6
110
0.54
0.73
1.3
1.5
—
—
—
0
0
5
25
2.02
0.73
1.2
1.3
—
—
—
0
0
13
86
1.54
0.67
1.2
1.3
3.6
3.9
g/l
—
7
58
13
86
1.54
0.67
1.2
1.3
—
—
—
0
0
13
86
1.54
0.67
1.2
1.3
6.9
7.5
g/l
—
8
62
226
2175
1.27
0.65
12.5
9.0
24.3
25.2
u/l
0.56
210
2072
0
20
0.00
0.60
0.0
1.2
—
—
—
0
0
0
20
0.00
0.60
0.0
1.2
—
—
—
0
0
0
20
0.00
0.60
0.0
1.2
—
—
—
0
0
233
2255
1.28
0.60
29.4
18.5
131.2
136.9
g/l
6.38
226
2207
0
21
0.00
0.60
0.0
1.0
—
—
—
0
0
0
21
0.00
0.60
0.0
1.0
—
39.9
—
0
14
0
21
0.00
0.60
0.0
1.0
—
600.7
—
0
15
0
22
0.00
0.59
0.0
2.0
—
—
—
0
0
0
23
0.00
0.58
0.0
1.1
—
—
—
0
0
12
81
1.50
0.58
1.2
1.3
2.6
3.1
g/l
—
7
59
21
159
1.35
0.57
3.3
4.0
94.3
84.5
ng/l
0.31
15
138
97
878
1.17
0.55
4.4
3.8
60.2
43.9
ng/l
0.33
77
639
139
1293
1.16
0.55
3.1
3.0
61.2
46.0
u/l
0.84
128
1198
195
2032
0.85
0.54
4.2
4.8
1.4
1.5
mmol/l
0.50
169
1851
9
62
1.47
0.53
1.4
1.3
—
—
—
0
0
195
2030
0.85
0.52
4.3
4.9
6.0
6.1
mmol/l
0.10
170
1826
197
2049
0.85
0.51
4.0
4.8
4.7
4.6
mmol/l
0.37
169
1871
200
1918
1.17
0.50
21.2
11.5
77.8
77.0
ml/min/173m2
0.21
166
1530
10
67
1.51
0.50
2.3
2.2
229.1
353.0
ug/l
—
10
59
7
48
1.47
0.47
1.1
1.7
—
—
—
0
0
37
434
0.83
0.45
2.2
2.6
0.7
0.8
ug/l
0.33
25
277
0
15
0.00
0.41
0.0
1.0
—
—
—
0
0
0
15
0.00
0.41
0.0
1.5
—
—
—
0
0
0
17
0.00
0.41
0.0
1.4
—
—
—
0
0
0
17
0.00
0.41
0.0
1.4
—
—
—
0
0
0
17
0.00
0.41
0.0
1.4
—
—
—
0
0
203
2095
0.87
0.40
4.5
5.4
2.8
2.7
mmol/l
0.32
175
1910
0
18
0.00
0.40
0.0
1.1
—
1.1
—
0
12
0
18
0.00
0.40
0.0
1.7
—
—
—
0
0
190
1966
0.88
0.38
3.7
4.3
1.3
1.3
mmol/l
0.07
164
1777
23
192
1.22
0.33
2.6
3.4
2.2
2.3
mmol/l
0.02
16
149
7
55
1.28
0.30
1.9
1.7
—
—
—
0
0
47
426
1.13
0.27
4.0
4.0
23.4
257.1
ng/l
1.84
37
344
28
245
1.16
0.26
2.5
2.4
18.8
24.5
%
1.29
23
210
5
38
1.32
0.23
1.0
1.2
28.1
28.7
iu/l
—
5
33
192
1873
1.09
0.23
4.7
4.6
2.1
2.6
mu/l
0.31
165
1676
5
39
1.29
0.23
1.8
1.6
—
—
—
0
0
14
116
1.22
0.22
1.1
1.2
140.9
222.0
u/ml
0.68
14
108
47
510
0.90
0.22
1.9
1.5
20.3
21.6
nmol/l
0.18
37
435
0
11
0.00
0.21
0.0
1.2
—
—
—
0
0
0
11
0.00
0.21
0.0
1.3
—
—
—
0
0
0
11
0.00
0.21
0.0
3.1
—
13.7
—
0
11
0
11
0.00
0.21
0.0
1.0
—
—
—
0
0
0
11
0.00
0.21
0.0
1.2
—
—
—
0
0
0
11
0.00
0.21
0.0
9.8
—
37.8
—
0
5
0
12
0.00
0.21
0.0
1.0
—
—
—
0
0
0
12
0.00
0.21
0.0
1.5
—
—
—
0
0
0
12
0.00
0.21
0.0
1.8
—
—
—
0
0
5
43
1.17
0.21
1.0
1.3
—
—
—
0
0
0
13
0.00
0.21
0.0
1.0
—
—
—
0
0
0
14
0.00
0.20
0.0
1.1
—
—
—
0
0
0
14
0.00
0.20
0.0
1.7
—
—
—
0
0
0
14
0.00
0.20
0.0
1.7
—
—
—
0
0
7
59
1.19
0.18
1.6
1.4
—
—
—
0
0
5
70
0.71
0.17
1.6
2.0
—
—
—
0
0
37
342
1.10
0.16
3.3
2.6
1.6
1.0
e6/l
0.52
28
193
194
1970
0.94
0.13
5.8
6.4
39.9
40.4
mmol/mol
0.40
167
1820
78
811
0.95
0.13
2.7
2.6
135.1
123.5
ug/l
0.17
65
738
101
979
1.05
0.12
4.7
3.7
0.0
0.0
estimate
0.00
24
163
86
889
0.95
0.11
2.4
1.9
95.9
95.8
pmol/l
0.00
39
444
29
311
0.92
0.11
1.7
1.7
29.3
29.5
s
0.05
29
302
13
115
1.14
0.10
4.7
2.7
0.1
0.1
e6/l
0.06
13
110
26
278
0.93
0.09
1.5
1.4
—
—
—
0
0
6
57
1.05
0.08
1.5
1.2
2.2
3.6
u/ml
—
6
12
48
500
0.95
0.08
2.2
2.1
3.5
3.0
mg/l
0.27
33
414
26
244
1.07
0.08
1.6
1.4
—
—
—
0
0
57
550
1.05
0.08
2.6
2.4
339.4
6158.3
umol/l
2.28
47
477
79
770
1.04
0.07
5.0
3.8
—
—
—
0
0
7
85
0.82
0.07
1.0
1.0
—
—
—
0
0
8
91
0.88
0.07
1.5
1.4
—
—
—
0
0
46
445
1.04
0.05
1.5
1.7
459.9
438.7
pmol/l
0.16
36
358
29
279
1.04
0.04
5.1
4.9
33.7
32.6
%
0.14
17
181
108
1093
0.98
0.03
2.7
2.6
—
—
—
0
0
98
992
0.98
0.03
5.6
5.0
0.0
0.0
estimate
0.00
25
163
99
1002
0.98
0.03
4.8
3.7
0.0
0.0
estimate
0.00
25
158
182
1811
1.02
0.02
19.3
13.5
38.9
40.2
%
1.00
110
1236
40
407
0.98
0.01
2.0
1.7
1266.9
1251.7
nmol/l
0.03
26
294
42
427
0.98
0.01
2.0
1.8
1.8
1.0
mg/l
0.85
32
326
32
321
1.00
0.00
3.8
2.9
0.5
2.4
e6/l
3.01
23
173
0
6
0.00
0.00
0.0
1.2
—
—
—
0
0
0
6
0.00
0.00
0.0
1.2
—
—
—
0
0
0
9
0.00
0.00
0.0
2.0
—
—
—
0
0
0
5
0.00
0.00
0.0
1.2
—
—
—
0
0
0
8
0.00
0.00
0.0
1.3
—
—
—
0
0
0
5
0.00
0.00
0.0
1.0
—
—
—
0
0
0
6
0.00
0.00
0.0
1.0
—
—
—
0
0
6
66
0.91
0.00
1.5
1.2
—
—
—
0
0
0
9
0.00
0.00
0.0
1.2
—
9.3
—
0
9
(40770918) von Willebrand factor (vWf).activity actual/normal in Platelet poor plasma by Immunoassay
0
5
0.00
0.00
0.0
4.2
—
89.2
—
0
5
0
5
0.00
0.00
0.0
1.0
—
—
—
0
0
0
7
0.00
0.00
0.0
1.0
—
—
—
0
0
0
7
0.00
0.00
0.0
1.0
—
—
—
0
0
0
6
0.00
0.00
0.0
1.2
—
—
—
0
0
0
5
0.00
0.00
0.0
1.2
—
—
—
0
0
0
5
0.00
0.00
0.0
1.0
—
—
—
0
0
6
66
0.91
0.00
1.5
1.2
—
—
—
0
0
0
5
0.00
0.00
0.0
1.0
—
3.1
—
0
5
0
5
0.00
0.00
0.0
1.4
—
—
—
0
0
0
6
0.00
0.00
0.0
1.0
—
—
—
0
0
Mortality – FinRegistry
↥This endpoint is excluded from FinRegistry analyses (omitted endpoint).
Relationships between endpoints
↥Index endpoint: C3_SALIVARYNAS_EXALLC – Malignant neoplasm of other and unspecified major salivary glands, excluding all cancers (controls excluding all cancers)
GWS hits: -
This endpoint is excluded from FinRegistry analyses (omitted endpoint).